AIP
HUMA icon

ARS Investment Partners’s Humacyte HUMA Stock Holding History

ARS Investment Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-99,419
Closed -$502K – 196
2025
Q1 		$502K Hold
99,419
– – 0.05% 113
2024
Q4 		$502K Buy
99,419
+15,000
+18% +$74.2K 0.05% 113
2024
Q3 		$459K Sell
84,419
-32,000
-27% -$211K 0.04% 114
2024
Q2 		$559K Buy
+116,419
New +$606K 0.05% 101

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ARS Investment Partners's HUMA Position: Q2 2025 in Review

ARS Investment Partners sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 99,419 shares — an estimated $502K sold.

ARS Investment Partners first reported a position in HUMA in Q2 2024 and held it in 4 quarters. The position peaked at $559K in Q2 2024. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

  • ARS Investment Partners reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
  • ARS Investment Partners sold 99,419 Humacyte shares in Q2 2025, an estimated $502K.
  • ARS Investment Partners first reported a position in Humacyte in Q2 2024 and held it in 4 quarters.
  • ARS Investment Partners's Humacyte position peaked at $559K in Q2 2024.
  • 156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on ARS Investment Partners's 13F filing for Q2 2025, filed 11 Aug 2025.